💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Simvastatin

CHEMBL1064 Phase 4 معتمد Small molecule
Half-Life
2 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
418.6 g/mol
LogP
4.7
Phase
4

A widely used statin that lowers LDL (bad) cholesterol and triglycerides by reducing the liver's production of cholesterol, helping to prevent heart attacks and strokes. Some research also suggests potential benefits in slowing cognitive decline, though its primary established use remains cardiovascular risk reduction.

الوزن الجزيئي

418,5700 g/mol

LogP

4,70

TPSA

72,80 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Stroke Hyperlipidemia Obesity Lymphoma Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Hepatitis C Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

تصنيفات الأدوية

C — C - Cardiovascular System

آلية العمل

Prodrug converted to active form that inhibits HMG-CoA reductase.

Pharmacokinetics (PK)

Half-Life 2 hours

Pharmacodynamics (PD)

الآلية

Prodrug converted to active form that inhibits HMG-CoA reductase.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21

                

                

                
                

                    
InChI

                    
InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H38O5

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
الروابط القابلة للدوران

                        
7

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
30

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            HMGCR (HMG-CoA Reductase)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            CYP3A4 (Cytochrome P450 3A4)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Simvastatin + Warfarin
                            
                        

                        
                        
Simvastatin modestly potentiates warfarin anticoagulation, leading to small but potentially clinically relevant INR increases.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Simvastatin + Cyclosporine
                            
                        

                        
                        
Cyclosporine raises simvastatin exposure by 6- to 10-fold through inhibition of CYP3A4, OATP1B1, and P-gp, creating an extremely high risk of rhabdomyolysis.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Simvastatin + Amlodipine
                            
                        

                        
                        
Amlodipine inhibits CYP3A4-mediated simvastatin metabolism, increasing simvastatin plasma concentrations and the risk of statin-associated myopathy and rhabdomyolysis.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A widely used statin that lowers LDL (bad) cholesterol and triglycerides by reducing the liver's production of cholesterol, helping to prevent heart attacks and strokes. Some research also suggests potential benefits in slowing cognitive decline, though its primary established use remains cardiovascular risk reduction.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Prodrug converted to active form that inhibits HMG-CoA reductase.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Simvastatin: Half-life: 2 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Simvastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1064.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 54454.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.